MGNX vs. HUMA, AMRN, PRTA, BNTC, HRTX, SNDL, VOR, AURA, ATXS, and AVTE
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Humacyte (HUMA), Amarin (AMRN), Prothena (PRTA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), SNDL (SNDL), Vor Biopharma (VOR), Aura Biosciences (AURA), Astria Therapeutics (ATXS), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.
MacroGenics vs. Its Competitors
Humacyte (NASDAQ:HUMA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.
MacroGenics has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.
Humacyte has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.
In the previous week, Humacyte had 1 more articles in the media than MacroGenics. MarketBeat recorded 4 mentions for Humacyte and 3 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.64 beat Humacyte's score of 0.48 indicating that MacroGenics is being referred to more favorably in the news media.
Humacyte currently has a consensus price target of $11.71, suggesting a potential upside of 390.14%. MacroGenics has a consensus price target of $5.71, suggesting a potential upside of 275.94%. Given Humacyte's stronger consensus rating and higher probable upside, research analysts plainly believe Humacyte is more favorable than MacroGenics.
44.7% of Humacyte shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 5.1% of Humacyte shares are held by insiders. Comparatively, 13.0% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Humacyte has a net margin of 0.00% compared to MacroGenics' net margin of -36.23%. Humacyte's return on equity of 0.00% beat MacroGenics' return on equity.
Summary
Humacyte beats MacroGenics on 9 of the 16 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
This page (NASDAQ:MGNX) was last updated on 7/16/2025 by MarketBeat.com Staff
Free MGNX Stock Alerts